Extended Data Fig. 2: Coagulation and platelet functional assays at baseline and post-treatment in LUMINA-1 patients. | Nature Medicine

Extended Data Fig. 2: Coagulation and platelet functional assays at baseline and post-treatment in LUMINA-1 patients.

From: Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial

Extended Data Fig. 2: Coagulation and platelet functional assays at baseline and post-treatment in LUMINA-1 patients.

Coagulation tests and platelet functional assays including a, activated prothrombin time b, prothrombin international normalized ratio and c, prothrombin time were collected after protocol amendment #3 at local laboratories to explore the mechanism of epistaxis and garetosmab mechanism of action. For patients already enrolled in the study, the blood samples for these assessments were collected at their next visit unless the assessment was performed in the last year. The blue box indicates the normal range across the local labs for the individual sites. d, The table shows the number of measurements and summary statistics for the coagulation tests and platelet functional assays at baseline. Q4W, every 4 weeks; SD, standard deviation.

Back to article page